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Abstract: Cholangiocarcinoma (CCA) comprises a group of heterogeneous biliary cancers with dismal
prognosis. the etiologies of most CCAs are unknown, but primary sclerosing cholangitis (PSC) is a risk
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factor. Non-invasive diagnosis of CCA is challenging and accurate biomarkers are lacking. We aimed
to characterize the transcriptomic profile of serum and urine extracellular vesicles (EVs) from patients
with CCA, PSC, ulcerative colitis (UC), and healthy individuals. Serum and urine EVs were isolated
by serial ultracentrifugations and characterized by nanoparticle tracking analysis, transmission
electron microscopy, and immunoblotting. EVs transcriptome was determined by Illumina gene
expression array [messenger RNAs (mRNA) and non-coding RNAs (ncRNAs)]. Differential RNA
profiles were found in serum and urine EVs from patients with CCA compared to control groups
(disease and healthy), showing high diagnostic capacity. the comparison of the mRNA profiles of
serum or urine EVs from patients with CCA with the transcriptome of tumor tissues from two cohorts
of patients, CCA cells in vitro, and CCA cells-derived EVs, identified 105 and 39 commonly-altered
transcripts, respectively. Gene ontology analysis indicated that most commonly-altered mRNAs
participate in carcinogenic steps. Overall, patients with CCA present specific RNA profiles in EVs
mirroring the tumor, and constituting novel promising liquid biopsy biomarkers.
Keywords: biomarkers; cholangiocarcinoma; extracellular vesicles; liquid biopsy; transcriptomics
1. Introduction
Cholangiocarcinomas (CCAs) are heterogeneous biliary malignancies characterized by dismal
prognosis. the incidence and mortality rates of these cancers are rapidly increasing globally, currently
accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies [1–3].
According to their anatomical localization, CCAs are classified into intrahepatic (iCCA), perihilar
(pCCA), or distal (dCCA). the etiology of most CCAs is unknown. However, several risk factors
have been described, including the presence of primary sclerosing cholangitis (PSC: 5–15% develops
CCA), a chronic cholestatic liver disease that is associated with autoimmune phenomena against
the intra- and extrahepatic bile ducts [1,4,5]. Importantly, 70–80% of patients with PSC concomitantly
present inflammatory bowel disease (IBD), mainly ulcerative colitis (UC), which is thought to precede
the development of the liver disease [4].
CCAs are generally asymptomatic in early stages, being therefore commonly diagnosed in
advanced phases when the disease is disseminated. Late diagnosis combined with the chemoresistant
nature of these tumors [6] highly compromise the current therapeutic options, mainly based on
surgery, significantly impacting on patient’s welfare and outcome [1,2]. the diagnosis of CCA is
usually conducted by combining clinical, biochemical, radiological, and histological information.
Imaging techniques usually rely on computed tomography (CT), magnetic resonance imaging
(MRI), magnetic resonance cholangiopancreatography (MRCP), positron emission tomography (PET),
percutaneous transhepatic cholangiography (PTC), endoscopic retrograde cholangiopancreatography
(ERCP), or endoscopic ultrasound depending on the tumor location [1,5,7]. However, imaging
proceedings have important limitations, as they are not accurate enough to determine the malignity of
the tumor masses, particularly in early stages, as well as to differentiate between the main primary
liver cancers, i.e., iCCA, hepatocellular carcinoma (HCC) or HCC-CCA mixed tumors, which is
fundamental to provide the appropriate standards of care. On the other hand, MRCP and histological
analysis (biopsy or brushing cytology) comprise the major diagnostic tools for PSC [4,8,9]. In addition,
the measurement of non-specific serum tumor biomarkers [i.e., carbohydrate antigen 19-9 (CA19-9)
and carcinoembryonic antigen (CEA)] is commonly conducted in order to help in the diagnosis of
CCA, but their low sensitivity (particularly in early stages of the disease) and specificity (also elevated
in some PSC patients without cancer), raise important concerns regarding their clinical utility [7,10].
Therefore, tumor biopsy is currently mandatory to confirm the diagnosis and staging of CCA, guiding
the clinical management of these patients [11]. Based on all of these diagnostic concerns, there is
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an urgent need to determine new accurate, non-invasive biomarkers for the early diagnosis of CCA,
particularly in patients at risk.
In the last decade, extracellular vesicles (EVs) have been envisioned as promising tools in the quest
for tumor biomarkers and as important mediators of disease pathogenesis [12]. EVs constitute
a heterogeneous population of lipid bilayered spheres (30 nm – 2 µm in diameter) containing diverse
biomolecules (e.g., proteins, nucleic acids, lipids, and metabolites), which are released by cells and found
in all biofluids (e.g., blood and urine) [13,14]. Taking into account their biogenesis, EVs may be classified
as exosomes, microvesicles (MV), and apoptotic bodies. These small vesicles participate in cell-to-cell
communications, modulating signaling pathways in pathobiology [13–17]. We previously reported
a differential proteomic profile of serum EVs from patients with CCA, HCC, or PSC, as well as from
healthy individuals, identifying accurate candidate biomarkers for the differential diagnosis of these
diseases [18]. Considering that tumor cells can also release RNAs encapsulated within EVs, and that
their profiles can mimic the cellular state/alterations, an extensive characterization of the RNA content
from serum and urine EVs from patients with CCA (and control conditions) might provide new
diagnostic biomarkers as well as therapeutic targets.
In this study, we aimed to characterize the RNA profile of serum and urine EVs from patients
with CCA, PSC, or UC, as well as healthy individuals, and identify candidate diagnostic biomarkers
mirroring their tumor cell expression within the liquid biopsy concept. For this purpose, the expression
of selected candidates was evaluated in human CCA tumor and surrounding healthy tissues from two
independent cohorts of patients [The Cancer Genome Atlas (TCGA) and Copenhagen], as well as in
cell cultures (CCA vs. normal) and EVs released by normal or tumor human cholangiocytes in vitro.
2. Materials and Methods
2.1. Patients
SerumandurinesamplesfrompatientswithCCA(n=12and23, respectively), PSC(n=6and5,respectively),
UC (n = 8 and 12, respectively), and healthy individuals (n = 9 and 5, respectively) were obtained from Donostia
UniversityHospital(SanSebastian,Spain),CrucesUniversityHospital(Bilbao,Spain),and“ComplejoHospitalario
de Navarra” (Pamplona, Spain). the Ethical Committees for Clinical Research from each participating institution
approved all the research protocols and all patients accepted to participate in the study and signed the written
consents to allow the use of their samples for biomedical research. Clinical characteristics of patients and tumors
are summarized in Supplementary Table S1. the diagnosis of PSC was based on the European Association
for the Study of the Liver (EASL) guidelines [19] by demonstrating the presence of bile duct alterations
(strictures or irregularities in intrahepatic and extrahepatic bile ducts) using MRCP after excluding secondary
causes of cholangitis. the diagnosis of UC was performed by combining endoscopic and histological studies,
mainly colonoscopy in parallel with hematoxylin and eosin (H&E) staining, after excluding other potential
diseases. Finally, CCA diagnosis was confirmed by histological analysis of tumor samples and/or through
the combination of clinical, biochemical and radiological approaches. Tumor stage was determined based on
the 7th edition of the American Joint Committee on Cancer (AJCC) classification.
RNA-seq data from the TCGA cohort (36 CCAs and 9 surrounding liver samples) [20],
downloaded as level 3 data through FireBrowse portal [BROAD Institute of MIT & Harvard, MA, USA
(source: https://gdac.broadinstitute.org/)], and whole transcriptome profiling [Human Transcriptome
(HT) BeadChips (Illumina Inc., San Diego, CA, USA)] of the “Copenhagen cohort” including 217 CCA
surgical specimens (153 iCCA, 43 pCCA, 15 dCCA, 6 unknown location), 143 normal surrounding liver
samples, and 9 normal intrahepatic bile ducts (GSE26566) [21,22] were used to evaluate the expression
of serum and urine biomarkers in tumor tissue.
2.2. Cell Cultures
Normal human cholangiocytes (NHCs) were isolated from normal liver tissue and characterized
as previously described [23–25]. Furthermore, two commercial human CCA cell lines (EGI1 and TFK1,
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Leibniz Institute DSMZ-German Collection of Microoganism and Cell Cultures, Germany) were used.
NHC and EGI1 cells were cultured in fully-supplemented DMEM/F-12 medium, as previously
described [23–25], while TFK1 cells were cultured in DMEM/F-12 supplemented with 10% fetal bovine
serum (FBS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin/streptomycin
(P/S; Gibco). Cells were seeded in 150 mm collagen-coated tissue culture dishes (4 × 106 cells)
with each respective cell culture medium and left for plate attachment overnight. Afterwards,
cells were washed with phosphate-buffered saline (PBS) and incubated with “EV recollection media”
(DMEM/F-12+Glutamax supplemented with 1% P/S, and without serum). After 48 h, cells were
harvested for RNA isolation and cell culture media was collected and stored at −80 ◦C for subsequent
EVs isolation. Cells were grown at 37 ◦C in a humidified chamber of 5% CO2. During all the experiments,
mycoplasm test was performed by conventional PCR and cells were tested as mycoplasm negative.
2.3. Isolation of EVs from Serum, Urine, and Cell Cultures
Serum, urine, and cell-derived EVs were isolated as previously described [18]. Briefly,
1 mL of serum, 50 mL of urine, or 300 mL of cell culture media (frozen at −80 ◦C) were thawed at
room temperature and further processed through serial differential ultracentrifugation steps at 4 ◦C.
First, in order to remove cell debris, serum, urine and cell culture media were centrifuged at 10,000× g
for 30 min and subsequently ultracentrifuged at 100,000× g for 75 min, to pellet the EVs, which were
then washed with PBS and pelleted again after ultracentrifugation at 100,000× g for 75 min. Finally,
the pelleted EV fraction was resuspended in 20 µL of PBS and then stored at −80 ◦C for further analysis.
2.4. Transmission Electron Microscopy (TEM)
For the characterization of EVs, the isolated fraction of EVs was stained negatively and analyzed
by TEM. EV samples were directly adsorbed onto glow-discharged (60 seg low discharging using
a PELCO easy-glow device) carbon-coated copper grid (300 mesh). Afterwards, grids were fixed
with 2% paraformaldehyde (PFA) in phosphate buffer (PB 0.2M pH 7.4) for 20 min and washed with
distilled water. Then, the contrast staining was made by incubating the grids with 4% uranyl acetate
(UA) at 4 ◦C for 15 min. TEM images were obtained by using TECNAI G2 20 C-TWIN high-resolution
transmission electron microscope, at an acceleration voltage of 200 kV.
2.5. Immunoblotting
Protein levels of both EV and endoplasmic reticulum markers (i.e., CD63 and CD81 vs. GRP78,
respectively) were evaluated in serum and urine EVs and in whole-cell extracts (WCEs) by immunobloting.
Total protein concentration was calculated with the Micro BCA protein assay kit (Thermo Fisher Scientific,),
following the manufacturer’s instructions. Loading buffer [50 mM Tris-HCl, 2% SDS, 10% glycerol and 0.1%
bromophenol blue, without β-mercaptoethanol or dithiothreitol (DTT)] was added to protein samples,
followed by heat denaturation at 95 ◦C for 5 min. Then, 10 and 4 µg of total protein from serum and urine
EVs, respectively, were separated by 12.5% sodium dodecyl sulfate-polyacrilamide gel electrophoresis
(SDS-PAGE) and electro-transferred onto a nitrocellulose membrane (GE Healthcare, Chicago, IL, USA)
and blocked with 5% skim milk powder/tris-buffered saline (TBS)-0.1% tween (TBS-Tween) for 1 h.
Afterwards, membranes were probed overnight at 4◦C with the appropriate primary antibodies
[anti-CD81 (BD Biosciences), anti-CD63 (DSHB), and anti-GRP78 (BD Biosciences, San Jose, CA, USA)]
at 1:500 dilution in blocking solution and, after three washes with TBS-Tween (5 min each), horseradish
peroxidase-conjugated secondary antibody (anti-mouse; Cell Signaling, Danvers, MA, USA) at a dilution
of 1:5000 (in milk blocking solution) were incubated for 1 h at room temperature. Membranes were
developed for protein detection using ECL plus (Thermo Fisher Scientific), with the iBright FL1500
Western Blot Imaging System (Thermo Fisher Scientific).
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2.6. EV Size and Concentration
Size distribution and concentration of EVs were evaluated by nanoparticle tracking analysis
(NTA) using a NanoSight LM10 System (Malvern, UK) further equipped with fast video capture
and a particle-tracking software. NTA post-acquisition settings were kept constant for all samples.
Each video was analyzed for obtaining the mean and mode vesicle size as well as particle concentration.
2.7. Total RNA Isolation
After EVs isolation, total RNA was extracted using the miRCURY™ RNA Isolation Kit
(Qiagen, Hilden, Germany) following manufacturer’s specifications. Afterwards, total RNA was
resuspended in 20µL of distilled H2O and later used for transcriptomic analysis. Regarding cell samples,
total RNA was extracted using the TRIzol® reagent according to the manufacturer’s instructions
(Life Technologies Corp., Carlsbad, CA, USA).
2.8. Illumina Gene Expression Array
Illumina HumanHT-12 WG-DASL V4.0 R2 expression beadchips were used to characterize gene
expression [messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs)]. the quality of RNA samples
was measured using a RNA Pico Chip Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
200 ng of RNA samples were used for the array. the cDNA synthesis, prequalification, amplification,
labeling and hybridization of the samples were performed following the WG-DASL HT Assay Lab
protocol (Illumina Inc.). the amplified cDNAs were hybridized to the diverse gene-probes of the array
and gene expression levels were detected by a HiScan scanner (Illumina Inc.). Raw data were extracted
with GenomeStudio analysis software (Illumina Inc.), in the form of GenomeStudio’s Final Report.
Raw expression data were background-corrected, log2-transformed and quantile-normalized using
the lumi R package [26] (Bioconductor repository, Chicago, IL, USA). To perform the Venn diagrams,
all the transcripts identified in at least one sample with a “detection p-value” < 0.01 were selected.
Afterwards, in the comparisons between groups, transcripts that were significantly identified in at least
20% of the samples (with a bilateral p-value < 0.05; independent samples two-tailed t-test, not assuming
equal variances) were considered for subsequent analysis.
2.9. Functional Enrichment Analysis
Functional analysis of candidate liquid biopsy RNA biomarkers was determined by gene ontology
(GO) enrichment of biological processes, molecular pathways and functions, by using the Functional
Enrichment analysis tool (FunRich) version 3.1.3 (Funrich Industrial Co. Ltd, Hong Kong) [27,28].
2.10. Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad Software,
San Diego, CA, USA). Data are shown as boxes and whiskers (min to max). When comparing two
groups, non-parametric Mann-Whitney or parametric t-Student tests were conducted. For comparisons
between more than two groups, non-parametric Kruskal-Wallis test followed by a posteriori Dunns
test of the parametric one-way analysis of variance (ANOVA) test followed by a posteriori Tukey’s post
hoc test were used. In order to calculate the diagnostic values of serum and urine RNA biomarkers,
allowing to discriminate between patients with CCA, PSC and UC, and healthy individuals, area under
the receiver operating characteristic curve (AUC) values were determined using the SPSS 20.0 software
(IBM, Ehningen, Germany), followed by the calculation of sensitivity (SEN) and specificity (SPE)
values, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio
(PLR), negative likelihood ratio (NLR), and accuracy index (AI). Differences were considered significant
when p < 0.05.
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3. Results
3.1. Characterization of Serum and Urine EVs from Patients with CCA, PSC, or UC, and Healthy Individuals
After isolation, serum and urine EVs were characterized by TEM, immunoblotting and NTA.
In resemblance with our previous findings using the same isolation protocol [18], TEM images showed
a typical rounded morphology in the isolated vesicles from both serum and urine (~100–200 nm),
corresponding to exosomes and/or small microvesicles (Figure 1A). By immunoblotting, the EV protein
markers CD63 and CD81 were highly enriched in the isolated EV fraction, when compared to total serum
or NHC whole-cell extracts (WCE), while the endoplasmic reticulum marker 78 kDa glucose-regulated
protein (GRP78) was completely absent in isolated serum and urine EVs but only found expressed
in WCE from NHCs (Figure 1B), substantiating a proper isolation and a high purity of the obtained
EVs. Regarding the size of EVs, NTA revealed no significant differences in the size of serum and urine
EVs among groups, presenting an average size of ~180 nm, in resemblance with serum and urine EV
concentration, which was found similar in the study population (Figure 1C).
Figure 1. Characterization of serum and urine EVs from patients with CCA, PSC, UC, and healthy
controls. In order to validate the protocol for EVs isolation, we used blood serum and urine from healthy
individuals. (A) TEM images of blood serum (left) and urine (right) EVs from healthy individuals
showcasing the typical round shape (~150 nm) and morphology. (B) Representative immunoblots of
the EV markers CD63 and CD81 (positive controls) and GRP78 (negative control) from EVs isolated
from serum (left) and urine (right) of healthy individuals that indicate an enrichment of EV markers
and a complete absence of the endoplasmic reticulum (ER) marker GRP78, compared to total serum
and whole cell extracts (WCEs) of normal human cholangiocytes (NHC). (C) Nanoparticle tracking
analysis (NTA) of serum (up) and urine (down) EVs revealing no differences in EV concentration
between CCA, PSC, UC, and healthy individuals and a similar EV mode (~180 nm).
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3.2. Differential RNA Profiles of Serum EVs from CCA, PSC, UC, and Healthy Individuals
The transcriptomic profiles of serum and urine EVs isolated from patients with CCA, PSC,
UC, and healthy controls were determined by RNA microarray-based transcriptomics (Illumina Inc.).
Transcriptomic data are available in GSE144521. Considering all the transcripts that were identified
in at least one sample included in any of the study groups (detection p-value < 0.01), a total of
25,084 transcripts were identified in serum EVs. Among them, 10,104 transcripts were identified
in serum EVs isolated from healthy individuals, in parallel with the identification of 11,124, 4204,
and 24,264 transcripts in serum EVs from patients with UC, PSC, and CCA, respectively, with 1617
of the identified transcripts being shared among all groups (Figure 2A). In all the study groups, the great
majority of the identified transcripts were mRNAs (9516, 10,526, 3949, and 23,029 transcripts found
in healthy individuals and patients with UC, PSC, or CCA, respectively), followed by non-coding
RNAs such as non-coding RNAs (mainly including pseudogenes, long non-coding RNAs (lncRNAs),
among others), microRNAs (miRNAs or miRs), and small nucleolar RNAs (snoRNAs) (Figure 2B;
Supplementary Table S2). Other types of RNAs, including small nuclear, miscellaneous, guide,
small cytoplasmic, antisense, RNase MRP, ribosomal, and telomerase RNAs were also detected.
Next, the transcriptome of serum EVs from the four study groups was determined and compared.
Specifically, 1932 transcripts were differentially identified in CCA vs. healthy individuals, 2888 in CCA
vs. PSC, and 2807 in CCA vs. “PSC, UC, and healthy individuals” combined as one unique control
(disease and healthy) group (Figure 3). Meanwhile, 866 transcripts were differentially identified in
serum EVs from patients with PSC compared with a group comprised of patients with UC and healthy
individuals (Supplementary Figure S1).
The analysis of candidate RNA biomarkers in serum EVs from CCA vs. healthy individuals pointed
out ring finger and FYVE like domain containing E3 ubiquitin protein ligase (RFFL), olfactory receptor
family 4 subfamily F member 3 (OR4F3), and the family with sequence similarity 107 member B
(FAM107B) as the mRNAs with the highest diagnostic capacity, presenting AUC values of 1.00,
1.00, and 0.991, respectively, along with the non-coding RNAs PMS1 homolog 2 mismatch repair
system component pseudogene 4 (PMS2L4), miR-604, and SNORA58 (AUC: 0.991, 0.944, and 0.926,
respectively) (Figure 3A). Since PSC is a well-known risk factor that increases the odds of developing
CCA, the transcriptomic profiles of serum EVs from patients with CCA vs. PSC were also compared.
In particular, the mRNA transcripts paraoxonase 1 (PON1), activating transcription factor 4 (ATF4),
and phosphoglycerate dehydrogenase (PHGDH) stood out as the best candidate biomarkers for
the differential diagnosis of CCA and PSC, all with AUC values of 1.00 (Figure 3B). Similarly,
the lncRNAs metastasis associated lung adenocarcinoma transcript 1 (MALAT1) and LOC100190986,
and the snoRNA SNORA11B (AUCs: 1.00) also presented a high accuracy for the identification of CCA
vs. PSC (Figure 3B). Of note, several mRNA and non-coding RNAs provided excellent diagnostic
values (AUC values up to 0.931 and 0.902, respectively) for the diagnosis of PSC, when compared with
patients with UC and healthy individuals (Supplementary Figure S1). Finally, general CCA transcript
biomarkers (compared to PSC, UC and healthy individuals combined as one unique control group)
were also identified and RFFL, zinc finger protein 266 (ZNF266) and OR4F3 constituted the mRNA
transcripts with the highest AUC values (1.00, 0.976, and 0.960, respectively) while miR-551B, PMS2L4,
and LOC643955 were the ncRNAs presenting the highest diagnostic capacity, displaying AUC values
of 0.909, 0.880, and 0.873, respectively (Figure 3C).
3.3. Selective mRNAs Present in Serum EVs from Patients with CCA Mirror Their Levels in Human Tumor
Tissue, CCA Cells In Vitro and EVs-Derived from Tumor Cholangiocytes
After identifying 2807 transcripts significantly altered in serum EVs from patients with CCA
compared to patients with PSC, UC, and healthy individuals, we evaluated if the expression of
these transcripts were also significantly changed in human CCA tissue, compared to non-tumor
surrounding tissue, in two independent international cohorts of patients (TCGA and the “Copenhagen”
cohorts). Importantly, 901 out of the 2807 selective RNA transcripts were also altered in the TCGA
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cohort, presenting the same trend of expression when compared to serum EVs, with 765 transcripts
being upregulated while 136 transcripts were downregulated in comparison to non-tumor tissue
(Figure 4A, left). These 765 transcripts were then cross-validated in the Copenhagen cohort,
in which we were able to identify 479 shared transcripts with the same expression tendency, with 391
being upregulated and 88 reduced when compared with surrounding liver tissue (Figure 4A, right).
After selecting the common mRNAs that share the same trend of expression in serum EVs and tumor
tissue of patients with CCA compared to controls, we next evaluated their expression levels in two
human CCA cell lines (EGI1 and TFK1) compared to NHCs in vitro, obtaining 156 commonly altered
transcripts (Figure 4B). Finally, we isolated EVs from these two CCA cell lines and from NHCs and,
after their characterization (Supplementary Figure S2) [18], we evaluated their transcriptomic content
and cross-validated the previous candidate transcripts, resulting in 105 mRNAs with shared altered
levels in serum EVs, tumor tissue, CCA cell lines, and in CCA-derived EVs (Figure 4C).
Figure 2. Comparative transcriptomic analysis of serum EVs from patients with CCA, PSC, or UC,
and healthy individuals. (A) Venn diagrams showing the number of transcripts identified per
group. Venn diagrams were generated using InteractiVenn web-based tool [29]. (B) Number of
transcripts identified within each study group, subclassified according to their type [messenger RNA
(mRNA), non-coding RNA (including mostly pseudogenes and long non-coding RNAs, among others),
miscelaneous RNA (miscRNA), guide RNA, microRNA (miRNA), small nucleolar RNA (snoRNA),
small nuclear RNA (snRNA), ribosomal RNA, telomerase RNA, small cytoplasmic RNA, antisense
RNA and RNase MRP RNA]. In all groups, mRNAs constitute the most abundantly identified RNAs,
followed by non-coding RNAs (pseudogenes, lncRNAs, and others), miRNAs, and snoRNAs.
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Figure 3. Differential transcriptomic profile of serum EVs and diagnostic capacity. Volcano plot
(−log10(p-value) and log2(fold-change); up left), heatmap of the differentially expressed transcripts
(up right) and diagrams with the diagnostic capacity with the highest AUC values of the 10 selected
mRNAs and 5 selected non-coding RNAs in serum EVs from (A) CCA vs. Healthy individuals;
(B) CCA vs. PSC; (C) CCA vs. (PSC + UC + Healthy individuals). Abbreviations: AI, accuracy index;
AUC, area under the receiver operating characteristic curve; CI, confidence interval; lncRNA,
long non-coding RNA; miRNA, microRNA; NLR, negative likelihood ratio; NPV, negative predictive
value; PLR, positive likelihood ratio; PPV, positive predictive value; SEN, sensitivity; snoRNA,
small nucleolar RNA; SPE, specificity.
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Figure 4. mRNAs commonly deregulated between serum EVs, CCA tumors from two independent
cohorts of patients, tumor cells in vitro and in CCA-derived EVs. mRNAs differentially abundant
in serum EVs from patients with CCA vs. (PSC + UC + Healthy individuals) were compared with
the transcriptome of: (i) patients with CCA from TCGA (n = 36) and “Copenhagen” (n = 217) cohorts,
(ii) CCA cells (EGI1 and TFK1) and cell-derived EVs compared to their respective control groups,
further selecting the ones that are commonly expressed. Heatmap of the differentially expressed
transcripts in (A) TCGA (left) and “Copenhagen” cohorts (right); (B) Whole-cell extracts from CCA
cells and NHCs; (C) Cell-derived EVs; (D) Gene ontology (GO: FunRich database [27]) analysis of
the 105 transcripts commonly altered in serum EVs, CCA human tumors, CCA cells and in cell-derived
EVs, highlighting the biological processes and pathways in which the identified transcripts are involved,
as well as their biological function. Abbreviations: CCA, cholangiocarcinoma, EVs, extracellular
vesicles; NHCs, normal human cholangiocytes; SL, surrounding liver; TCGA, the cancer genome atlas.
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Gene ontology (GO) analysis revealed that the 105 mRNAs previously identified code for
proteins mainly involved in pivotal processes during carcinogenesis. Specifically, metabolic pathways
(nucleic acid and protein metabolism), cell communication, signal transduction, energy, and cell
growth/maintenance pathways constituted the most represented biological processes in which
the identified mRNA transcripts are involved, therefore impacting in important cancer-promoting
pathways, such as cell cycle regulation, mitosis, epithelial-mesenchymal transition (EMT), DNA repair,
and telomere maintenance (Figure 4D). Of note, the expression of some of these transcripts positively
correlated with worse disease severity (i.e., advanced tumor stage and tumor dedifferentiation)
in the TCGA and Copenhagen cohorts (Supplementary Figure S3). Among all the 105 transcripts
identified, c-Maf inducing protein (CMIP), glutamate decarboxylase 1 (GAD1), nucleoside diphosphate kinase
1 (NME1), CDP-diacylglycerol synthase 1 (CDS1), and cyclin-dependent kinases regulatory subunit 1 (CKS1B)
constituted the best liquid biopsy candidate biomarkers, as their levels were increased in serum EVs
and presented AUC values of 0.957, 0.928, 0.899, 0.893, and 0.891, respectively, for the diagnosis
of CCA in comparison with patients with PSC, UC, and healthy individuals grouped together
(Figure 5A–E). Importantly, a panel comprised of CMIP, NME1 and CKS1B provided the maximum
diagnostic capacity (AUC: 1.000) for CCA in comparison with the group containing healthy individuals
and patients with PSC and UC (Figure 5F). the mRNA levels of the aforementioned transcripts were
also markedly increased in serum EVs from patients with CCA compared with the ones isolated from
PSC patients, therefore potentially constituting novel biomarkers for the differential diagnosis of CCA
and PSC. the mRNA expression levels of these genes were also increased in CCA tumor samples
from the TCGA and Copenhagen cohorts, compared with either normal surrounding liver tissue or
normal intrahepatic bile ducts, being also found upregulated in CCA tumor cells, compared to NHCs,
and also in CCA-derived EVs (Figure 5A–E). Noteworthy, besides providing the best diagnostic value
among all the liquid biopsy candidates, CMIP mRNA levels were found particularly increased in
poorly-differentiated tumors in the Copenhagen cohort (Supplementary Figure S3A).
3.4. Differential Transcriptomic Profiles of Urine EVs from Patients with CCA, PSC, UC, and Healthy Individuals
In urine EVs, a total of 11,323, 23,920, 22,159, and 26,066 RNAs were identified in healthy
individuals and patients with UC, PSC, or CCA, respectively, accounting for a total of 27,319 transcripts
detected (Figure 6A). Regarding the type of transcripts found, similar distribution was observed
when compared with the profile obtained in serum EVs, abundantly detecting mRNAs, followed
by ncRNAs such as pseudogenes and lncRNAs, miRNAs, and snoRNAs (Figure 6B). the analysis
of urine EVs revealed differential transcriptomic profiles between patients with CCA, PSC, or UC,
and healthy individuals. In particular, 2386 transcripts were differentially identified in urine EVs from
patients with CCA vs. healthy individuals, 1999 in CCA vs. PSC, and 1329 in CCA vs. other diseases
(PSC and UC) and healthy individuals combined in a single group. In this regard, INO80 complex
subunit D (INO80D), MAP6 domain containing 1 (MAP6D1) and Ras-related GTP binding D (RRAGD)
constituted the most promising mRNA biomarkers in urine EVs isolated from patients with CCA,
in comparison with healthy individuals, displaying AUC values of 1.000. Of note, the lncRNA HLA
complex group 4 (HCG4), miR200c, and the lncRNA LOC100134868 also presented high accuracies for
the diagnosis of CCA, with AUC values of 0.930, 0.904, and 0.896, respectively (Figure 7A). Regarding
the differential identification of CCA and PSC, the mRNA transcripts CAP-Gly domain containing linker
protein 3 (CLIP3), Vascular cell adhesion molecule 1 (VCAM1) and Tripartite motif containing 33 (TRIM33)
displayed excellent AUC values (0.965), in parallel with the pseudogene ATP synthase F1 subunit
epsilon pseudogene 2 (ATP5EP2), the lncRNA LOC100134713, and the Small nucleolar RNA, H/ACA
box 8 (SNORA8) (AUC: 0.939, 0.930, and 0.922, respectively), thus allowing to distinguish patients
with CCA and PSC with high sensitivity and specificity values (Figure 7B). When comparing urine
EVs from patients with PSC vs. UC and healthy individuals considered as a unique group, several
mRNA and non-coding RNAs arose as potential biomarkers for the diagnosis of PSC, with AUC
values up to 1.000 and 0.965, respectively (Supplementary Figure S4). Finally, by comparing CCA to
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the group containing patients with other diseases (PSC and UC) and healthy individuals, the mRNA
metallothionein 1F (MT1F), glutathione peroxidase 3 (GPX3), and lactate dehydrogenase 4 (LDH4) stood out
as the ones with the best AUC values (0.915, 0.897, and 0.894, respectively), along with the ncRNAs U11
small nuclear (RNU11), LOC257358, and vault RNA 1-1 (VTRNA1-1) (0.830, 0.812, and 0.777, respectively)
(Figure 7C), therefore constituting promising urine EV biomarkers for the accurate diagnosis of CCA.
Figure 5. Cont.
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Figure 5. Selected liquid biopsy biomarkers for CCA. From the 105 mRNAs commonly altered in
serum EVs, CCA human tumors, CCA cells and in cell-derived EVs compared to their corresponding
controls, 5 biomarkers were selected based on their diagnostic capacity. Box plot diagrams with
the mRNAs abundance in serum EVs (left), CCA tumors from the TCGA, and “Copenhagen” cohorts,
CCA cells and cell-derived EVs (right), compared to their respective controls, for (A) c-Maf inducing
protein (CMIP), (B) glutamate decarboxylase 1 (GAD1), and (C) NME/NM23 nucleoside diphosphate kinase
1 (NME1); (D) CDP-diacylglycerol synthase 1 (CDS1), and (E) CDC28 protein kinase regulatory subunit
1B (CKS1B). (F) Diagnostic prediction (ROC curves and AUC values) of the selected serum liquid
biopsy biomarkers and for the combination of CMIP, NME1 and CKS1B for the diagnosis of CCA
in comparison with (PSC + UC + Healthy individuals). Abbreviations: AUC, area under the receiver
operating characteristic (ROC) curve; EVs, extracellular vesicles; NHC, normal human cholangiocyte;
NBD, normal bile ducts; SL, surrounding liver; TCGA, the cancer genome atlas.
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Figure 6. Comparative transcriptomic analysis of urine EVs from patients with CCA, PSC, or UC,
and healthy individuals. (A) Venn diagrams showing the number of transcripts identified per
group. Venn diagrams were generated using InteractiVenn web-based tool [29]. (B) Number of
transcripts identified within each study group, subclassified according to their type [messenger RNA
(mRNA), non-coding RNA (including mostly pseudogenes and long non-coding RNAs, among others),
miscelaneous RNA (miscRNA), guide RNA, microRNA (miRNA), small nucleolar RNA (snoRNA),
small nuclear RNA (snRNA), ribosomal RNA, telomerase RNA, small cytoplasmic RNA, antisense
RNA and RNase MRP RNA]. In all groups, mRNAs constitute the most abundantly identified RNAs,
followed by non-coding RNAs (pseudogenes, lncRNAs, and others), miRNAs, and snoRNAs.
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Figure 7. Differential transcriptomic profile of urine EVs and diagnostic capacity. Volcano plot
(−log10(p-value) and log2(fold-change); up left), heatmap of the differentially expressed transcripts
(up right) and diagrams with the diagnostic capacity with the highest AUC values of the 10 selected
mRNAs and 5 selected non-coding RNAs in serum EVs from (A) CCA vs. Healthy individuals;
(B) CCA vs. PSC; (C) CCA vs. (PSC + UC + Healthy individuals). Abbreviations: AI, accuracy index;
AUC, area under the receiver operating characteristic curve; CI, confidence interval; miRNA, microRNA;
lncRNA, long non-coding RNA; miscRNA, miscellaneous RNA; NLR, negative likelihood ratio;
NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value;
SEN, sensitivity; snRNA, small nuclear RNA; snoRNA, small nucleolar RNA; SPE, specificity; vtRNA,
vault RNA.
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3.5. Selective mRNAs Present in Urine EVs from Patients with CCA Mimic Their Levels in Human Tumor
Tissue, CCA Cells In Vitro, and EVs-Derived from Tumor Cholangiocytes
Similar to our previous analysis on the serum EV biomarkers identified in patients with
CCA, compared to all the other study groups, we now selected the 1329 RNA transcripts that
were significantly altered in urine EVs from patients with CCA and compared their expression
levels with CCA and surrounding tumor tissues from both TCGA and Copenhagen cohorts.
After performing a comprehensive analysis of these mRNAs in the TCGA cohort, we were able
to identify 390 dysregulated transcripts (305 upregulated and 85 downregulated) that are commonly
altered in urine EVs and in tumor samples from patients with CCA (Figure 8A, left). Additionally,
compared to the changes observed in urine EVs, 259 transcripts also shared the same pattern of
alteration in the Copenhagen cohort, with 206 transcripts presenting increased expression while
53 transcripts were reduced, when compared with surrounding liver (Figure 8A, right). the comparison
of these 259 transcripts with the differential transcriptome of CCA cell lines compared to NHCs,
revealed 84 shared mRNAs that were altered in CCA cells, with 69 being upregulated and 15 displaying
decreased expression (Figure 8B). In EVs isolated from CCA and NHC cell cultures, we were able
to identify 39 mRNAs (34 upregulated and 5 downregulated) commonly altered with urine EVs,
tumor tissue, and CCA cells (Figure 8C).
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Figure 8. mRNAs commonly deregulated between urine EVs, CCA tumors from two independent
cohorts of patients, tumor cells in vitro and in CCA-derived EVs. mRNAs differentially abundant
in serum EVs from patients with CCA vs. (PSC + UC + Healthy individuals) were compared
with the transcriptome of: (i) patients with CCA from the Cancer Genome Atlas TCGA (n = 36)
and “Copenhagen” (n = 217) cohorts, (ii) CCA cells (EGI1 and TFK1) and cell-derived EVs compared
to their respective control groups, further selecting the ones that are commonly expressed. Heatmap
of the differentially expressed transcripts in (A) TCGA (left) and “Copenhagen” cohorts (right);
(B) Whole-cell extracts from CCA cells and normal human cholangiocytes (NHCs); (C) Cell-derived
EVs; (D) Gene ontology (GO: FunRich database [27]) analysis of the 105 transcripts commonly altered in
serum EVs, CCA human tumors, CCA cells and in cell-derived EVs, highlighting the biological processes
and pathways in which the identified transcripts are involved, as well as their biological function.
Abbreviations: EVs, extracellular vesicles; NHC, normal human cholangiocyte; SL, surrounding liver;
TCGA, the cancer genome atlas.
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In order to evaluate the role of these transcripts in carcinogenesis, we conducted a GO analysis
and observed that, in resemblance with what we previously found in serum EVs, these mRNA transcripts
code for proteins that are predominantly related with tumor development and progression, namely
metabolic pathways (nucleic acids and protein metabolism), signal transduction, cell communication,
EMT and immune response. Although less represented, some transcripts were also linked to
energy and cell growth/maintenance pathways (Figure 8D). In this regard, the transcripts ubiquitin
conjugating enzyme E2 C (UBE2C) and serine protease inhibitor B1 (SERPINB1) arose as potential liquid
biopsy biomarkers, being increased in urine EVs isolated from patients with CCA in comparison
to a group containing patients with PSC, UC and healthy controls (Figure 9A,B). Combining these
urine biomarkers into one panel increased their diagnostic accuracy, providing an AUC value of
0.812 for the diagnosis of CCA (Figure 9C). Noteworthy, the expression levels of these transcripts
were also markedly upregulated in CCA tumor samples from the TCGA and Copenhagen cohorts,
when compared with both normal surrounding liver specimens and/or normal intrahepatic bile
ducts, presenting also increased expression in CCA cells and in CCA-derived EVs, when compared
with NHCs (Figure 9A,B). Importantly, SERPINB1 mRNA levels increased with disease severity in
the Copenhagen cohort, being particularly overexpressed in advanced tumor stages compared with
early stage CCAs (Supplementary Figure S5A). Furthermore, although not being presented as one of
the best liquid biopsy candidate, Tctex1 domain containing 2 (TCTEX1D2) levels were found upregulated
in poorly-differentiated tumors compared with well-differentiated ones (Supplementary Figure S5B).
Figure 9. Potential urine liquid biopsy markers for CCA. From the 39 transcripts commonly found
in serum EVs and differentially expressed in patient samples, CCA cells and in cell line-derived
EVs, 2 potential urine liquid biopsy markers with the best diagnostic capacity were selected.
Box plot diagrams with the mRNA transcript abundance in urine EVs (left) and the expression
in the TCGA and “Copenhagen” cohorts, cholangiocyte cell lines and cell line-derived EVs (right)
for (A) Ubiquitin conjugatin enzyme E2 C (UBE2C) and (B) Serine proteinase inhibitor B1 (SERPINB1).
(C) Diagnostic prediction (ROC curves and AUC values) of the selected urine liquid biopsy markers
and from the combination of UBE2C and SERPINB1 for the diagnosis of CCA in comparison
with (PSC + UC + Healthy individuals). Abbreviations: AUC, area under the receiver operating
characteristic curve; EVs, extracellular vesicles; NHC, normal human cholangiocyte; NBD, normal bile
ducts; SL, surrounding liver; TCGA, the cancer genome atlas.
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4. Discussion
In the last decade, a considerable effort has been made to identify novel non-invasive biomarkers
for the early and accurate diagnosis of CCA [7]. Here, we report for the first time the differential
RNA profile of serum and urine EVs from patients with CCA, PSC, or UC, and healthy individuals,
identifying new potential biomarkers with high diagnostic capacity. Noteworthy, some of the altered
mRNAs were similarly changed in CCA tumors from two independent cohorts of patients, and in
tumor cells and CCA-derived EVs in vitro, highlighting their utility as liquid biopsy biomarkers as
well as their potential value as targets for therapy.
High-throughput omic approaches have been of great help in order to find potential new candidate
biomarkers. In fact, the identification of the proteomic content of EVs, as well as certain circulating
proteins, in biofluids have already provided candidate biomarkers in bile, serum, and urine from
patients with CCA [18,30–32]. We have recently described the differential proteomic profiles of
serum EVs from patients with CCA, compared to HCC, PSC, and healthy individuals, reporting new
potential protein biomarkers with high diagnostic capacity [18] that must be internationally validated
by ELISA technology. Nevertheless, a full transcriptomic analysis in distinct body fluids (in particular
EVs) from these patients has never been conducted and might result in the identification of novel,
accurate biomarkers for the diagnosis of CCA. Although proteins are usually more stable than mRNAs,
their presence within EVs provides them protection from degradation; moreover, RNAs are usually
easier to detect and quantify, even when found at very low levels, which may help in their faster
translation into the clinic [33]. In fact, circulating small ncRNAs are found in all biofluids (including
serum and urine), mainly due to their remarkable resistance to RNase degradation. High circulating
RNase levels contribute to a low abundance of other types of RNAs (mRNAs) and significantly
compromise their easy and reliable detection [34]. Still, specific RNAs can be released from cancer
cells into biofluids, allowing their identification and further determination of their potential value as
biomarkers, as they may mirror the cellular state within the concept of liquid biopsy. For instance, some
RNA transcripts were already evidenced and found increased in plasma, as is the case of telomerase
reverse transcriptase (hTERT) that showed diagnostic and prognostic value for prostate cancer, being
a good predictor of recurrence [35,36]. Similarly, the levels of the long non-coding RNA prostate cancer
associated 3 (PCA3) were abundantly found in urine of patients with prostate cancer, constituting
a promising non-invasive biomarker for the diagnosis of that cancer [37,38]. the levels of several
miRNAs were also reported altered in serum, plasma, and urine of patients with gastrointestinal
cancers, including CCA, constituting also potential novel biomarkers for cancer diagnosis [7,33,39–41].
Taking advantage from our previously reported EV isolation protocol [18], we have here also
settled up the protocol for the isolation of urine EVs. By analyzing the transcriptomic profile of
serum and urine EVs from patients with CCA, the present study was pioneer in identifying novel
potential RNA biomarkers with high diagnostic capacity for CCA. Noteworthy, some of these new
RNA biomarkers were also significantly altered in CCA tissue from the two international cohorts
of patients and further disturbed in CCA cell lines and in EVs secreted from these tumor cell lines,
when compared with NHCs. Consequently, these biomarkers are mirroring what is happening in
the tumor tissue, since the disturbances observed in tumor biopsies (and CCA cell lines) that are later
secreted in EVs and released into the bloodstream are amenable for detection either in serum or urine
(Figure 10). This constitutes a novel and innovative liquid biopsy approach where we are able to detect
specific alterations that are observed in tumor tissue without obtaining tumor samples, harboring
a high diagnostic value. In the future, evaluating the relevance of these biomarkers in predicting
prognosis and in guiding therapeutic decisions is envisioned.
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Figure 10. Novel liquid biopsy approach for cholangiocarcinoma. CCA tumor cells display distinct RNA
expression profiles which are later released into circulation in EVs, containing potential biomarkers
for CCA, that are amenable for detection in serum and urine, thus constituting a novel liquid
biopsy approach.
Taking into consideration the 105 potential liquid biopsy biomarkers that were identified in serum,
we herein reported the best five serum biomarkers that display excellent diagnostic accuracy: CMIP,
GAD1, NME1, CDS1, and CKS1B. Importantly, these novel potential biomarkers might constitute better
CCA biomarkers than CA19-9 since the AUC values that we herein obtained (up to 0.891) are higher
than the diagnostic capacity reported in a systematic review and a meta-analysis, in which the AUC
value for CA19-9 was 0.830 [42]. Despite the potential diagnostic value of these transcripts, considering
that they are concomitantly increased in tumor tissue in two international independent cohorts,
we postulate that they also might play a pivotal pathological role during cholangiocarcinogenesis. Still,
no studies have currently addressed the involvement of these biomolecules in CCA, although several
works already valued their role in other types of cancer. For instance, the transcription factor CMIP
was previously shown to be increased in human gastric cancer and glioma tumors, contributing to
tumor proliferation and metastasis [43,44]. Furthermore, high CMIP levels were associated with worse
prognosis (recurrence-free and overall survival) in gastric and breast cancers [43,45] and were related
with herceptin resistance in HER2-positive gastric cancer cells [46]. Similarly, the enzyme encoded
by GAD1 gene, which catalyzes the conversion of L-glutamic acid to γ-aminobutyric acid, has been
found overexpressed in several types of tumors, including lung adenocarcinoma [47], nasopharyngeal
carcinoma [48], oral squamous cell carcinoma [49], prostate cancer [50], and brain metastasis [51],
being also found upregulated in colon and HCC cells in vitro [52]. In parallel, high GAD1 levels
were also shown to correlate with the pathological stage of patients with lung adenocarcinoma,
positively correlating with metastasis and with worse recurrence-free survival [47]. Regarding NME1,
its relevance in cancer is still controversial. a meta-analysis evaluated the prognostic value of NME1
in patients with digestive system neoplasms (including patients with HCC and gallbladder cancer,
but not CCA) and reported that high NME1 levels are correlated with well-differentiated tumors
and with less-severe cancer stages, with no evident correlation with prognosis [53]. In agreement
with the reported metastasis-suppressing role of NME1, patients with HCC presenting lower protein
levels of NME1 displayed increased metastatization [54]. In patients with HCC [55] and in two animal
models of HCC [56], NME1 expression was found upregulated in comparison with non-tumor tissue,
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while knocking-out NME1 resulted in an increased number of lung metastasis [56]. Still, increased levels
of NME1 negatively correlated with disease stage while NME1 upregulation was positively correlated
with poor overall survival and with higher recurrence [55]. Furthermore, in melanoma patients,
a NME1-related gene expression signature was reported and linked with increased overall survival [57],
pinpointing for a potential tumor suppressor role, but new pro-oncogenic roles, mainly related with
the expansion of stem-like features and tumor growth, were recently reported [58]. Considering
CDS1, a DNA damage-related function is well-known [59,60] and a screening of several cancer cell
lines highlighted that the expression levels of CDS1 are dependent on p53 activity, being inversely
correlated with the presence of a functional p53 [61]. Although CDS1 is thought to act as a tumor
suppressor, there is no much information in this field. For instance, CDS1 was shown to be decreased
in patients with HCC, likely as a result of promoter hypermethylation [62]. Nevertheless, its relevance
for hepato- and/or cholangiocarcinogenesis is yet to be unveiled. Additionally, CKS1B represents
an oncogene that has been reported increased in retinoblastoma, HCC, nasopharyngeal carcinoma
and multiple myeloma [63–67]. Importantly, CKS1B upregulation has been positively related to
increased proliferation, migration, angiogenesis, invasion and chemoresistance, being further related
with lymph node metastasis and worse prognosis. Overall, regarding these genes, although nothing
is still reported in CCA pathogenesis, they potentially constitute new key carcinogenic players that
deserve further attention in the near future.
Considering the potential urine liquid biopsy biomarkers, we herein were able to report
39 transcripts that are differentially found in EVs from patients with CCA, sharing their pattern
of expression in CCA patients from the TCGA and Copenhagen cohorts and in CCA cells and in
CCA-derived EVs in vitro. In fact, this number of transcripts corresponds to almost one-third of
the identified serum liquid biopsy biomarkers, which might indicate that serum constitutes a richer
source of potential CCA biomarkers. In this line, we have to bear in mind that EVs released from
tumor masses directly enter into the bloodstream and their analysis might better mirror what is
currently happening in the tumor. Furthermore, glomerular filtration might impact on the detected
tumor-released EVs, therefore explaining the reduced number of urine liquid biopsy biomarkers.
Still, urine analysis is considered the less invasive procedure for the diagnosis of cancer so far
and we here describe some potential new urine biomarkers with good diagnostic values that are also
altered in tumor samples. For instance, UBE2C is commonly upregulated in intestinal-type gastric
cancer, ovarian cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma,
HCC, and non-small cell lung cancer [68–74]. Remarkably, increased UBE2C expression promotes
chromosomal instability, cell cycle progression, proliferation and EMT, being positively correlated with
worse clinical outcomes, mainly overall survival, lymph node metastasis, and progression-free survival.
Of note, experimental inhibition of UBE2C suppressed the malignant phenotypes, surpassing cisplatin
resistance in ovarian and non-small cell lung cancers [69,74], in parallel with overcoming sorafenib
resistance in HCC [73]. On the other hand, the reports regarding SERPINB1 are still controversial.
SERPINB1 levels were found decreased in patients with prostate cancer, glioma, and HCC, favoring
migration and invasion [75–77], while displaying increased expression in cells and patients with oral
cancer, correlating with high motility and cell migration in vitro [78]. Importantly, SERPINB1 levels
were shown to predict the outcome of cisplatin-based chemotherapies in melanoma [79] and the value
of this transcript/protein as surrogate marker for CCA should be evaluated in the future.
Besides identifying novel CCA biomarkers, we were also able to identify novel potential RNA
transcripts for the differential diagnosis of CCA vs. PSC. Distinguishing between PSC-associated
benign biliary strictures and early-stage CCA lesions is challenging. In fact, magnetic resonance
imaging (MRI) has a limited resolution for this differential diagnosis [5,80] and performing conventional
cytology and/or fluorescence in situ hybridization (FISH) after invasive biliary brushing by endoscopic
retrograde cholangiography only display a moderate diagnostic accuracy and increase the odds for
procedure-related complications, including pancreatitis and cholangitis [5,80]. In fact, several serum
and urine EV transcripts provided the maximum diagnostic capacity for the differential diagnosis
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of CCA and PSC, constituting potential biomarkers for the early diagnosis of CCA in patients with
PSC. Although this work was mainly focused on the study of mRNA transcripts, several ncRNAs
stood out as novel potential diagnostic biomarkers for the diagnosis of CCA. In particular, the levels of
the lncRNA MALAT1 are increased in serum EVs from patients with CCA compared to PSC, displaying
an AUC value of 1.00. In this regard, MALAT1 was found upregulated in HCC, contributing to
tumor development and progression [81–84], as well as identified in HCC-derived exosomes [85].
MALAT1 is also increased in colon cancer cells, directly binding to miR-663a, thus acting as a competing
endogenous lncRNA; as a result, important cancer-related miR-663a targets (TGFB1, PIK3CD, P21, JunB,
and JunD) were affected [86]. These results encourage future studies on the potential role of MALAT1
in CCA. In addition, increased levels of miR-604 and miR-551B in serum EVs from patients with CCA
also provided excellent diagnostic capacities (up to 0.944) for CCA and some studies already started
to evaluate their involvement in carcinogenesis and as diagnostic biomarkers [87–90]. Considering
the high resistance of small ncRNAs to RNase degradation, additional efforts should be employed in
order to validate their diagnostic accuracy.
Overall, here we reported for the first time the differential RNA profiles of serum and urine EVs
of patients with CCA, PSC, or UC, compared to healthy individuals, identifying novel non-invasive
accurate biomarkers for CCA that mirror their expression in tumor tissue, thus constituting a novel
liquid biopsy approach. the newly identified RNA biomarkers might markedly facilitate the diagnosis
of these diseases and should be taken into consideration in future studies. These results pave the path
not only for the discovery of new biomarkers but also for new potential therapeutic targets, as they
may participate in disease pathogenesis. However, these results need to be now validated in large,
international, and well-characterized cohorts of patients (and also including patients with CCA on
a PSC background), in order to ascertain the diagnostic accuracy of the proposed biomarkers and then
translate our findings into clinics. More importantly, it is pivotal to validate these results with easy
transferable techniques [e.g., quantitative PCR (qPCR) and droplet digital PCR (ddPCR), among others],
in order to avoid the time-consuming steps and equipment demands for EVs isolation. In this way,
we will be a little bit closer to see the use of accurate non-invasive diagnostic biomarkers for CCA
at the clinics.
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distal CCA; ddPCR, droplet digital PCR; CKS1B, CDC28 protein kinase regulatory subunit 1B; DTT, dithiothreitol;
ERCP, endoscopic retrograde cholangiopancreatography; EVs, extracellular vesicles; FAM107B, family with
sequence similarity 107 member B; FBS, fetal bovine serum; GAD1, glutamate decarboxylase 1; GO, gene ontology;
GPX3, glutathione peroxidase 3; Grp78, 78 kDa glucose-regulated protein; HCC, hepatocellular carcinoma; HCG4,
HLA complex group 4; H&E, hematoxylin and eosin; hTERT, telomerase reverse transcriptase; IBD, inflammatory
bowel disease; iCCA, intrahepatic CCA; INO80D, INO80 complex subunit D; LDH4, lactate dehydrogenase 4;
MALAT1, metastasis associated lung adenocarcinoma transcript 1; MAP6D1, MAP6 domain containing 1; miRNA,
microRNA; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging; MT1F,
metallothionein 1F; MVs, microvesicles; NHCs, normal human cholangiocytes; NLR, negative likelihood ratio;
NME, NME/NM23 nucleoside diphosphate kinase 1; NPV, negative predictive value; NTA, nanoparticle tracking
analysis; pCCA, perihilar CCA; OR4F3, olfactory receptor family 4 subfamily F member 3; PBS, phosphate-buffered
saline; PCA3, prostate cancer associated 3; PET, positron emission tomography; PFA, paraformaldehyde; PHGDH,
phosphoglycerate dehydrogenase; PLR, positive likelihood ratio; PMS2L4, PMS1 homolog 2 mismatch repair
system component pseudogene 4; PON1, paraoxonase 1; PPV, positive predictive value; P/S, penicillin/streptomycin;
PSC, primary sclerosing cholangitis; PTC, percutaneous transhepatic cholangiography; qPCR, quantitative PCR;
RFFL, ring finger and FYVE like domain containing E3 ubiquitin protein ligase; RRAGD, Ras related GTP
binding D; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis; SEN, sensitivity; SERPINB1,
serpin family B member 1; SNORA8, small nucleolar RNA, H/ACA box 8; SPE, specificity; TBS, tris-buffered saline;
TCGA, the cancer genome atlas; TCTEX1D2, Tctex1 domain containing 2; TEM, transmission electron microscopy;
TRIM33, tripartite motif containing 33; UA, uranyl acetate; UBE2C, ubiquitin conjugating enzyme E2 C; UC,
ulcerative colitis; VCAM1, vascular cell adhesion molecule 1; VTRNA1-1, vault RNA1-1; WCEs, whole-cell
extracts; ZNF266, zinc finger protein 266.
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